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Abstract
Background: Informed consent is one of the key elements in biomedical research. The introduction of electronic informed
consent can be a way to overcome many challenges related to paper-based informed consent; however, its novel opportunities
remain largely unfulfilled due to several barriers.
Objective: We aimed to provide an overview of the ethical, legal, regulatory, and user interface perspectives of multiple
stakeholder groups in order to assist responsible implementation of electronic informed consent in biomedical research.
Methods: We conducted a systematic literature search using Web of Science (Core collection), PubMed, EMBASE, ACM
Digital Library, and PsycARTICLES. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines
were used for reporting this work. We included empirical full-text studies focusing on the concept of electronic informed consent
in biomedical research covering the ethical, legal, regulatory, and user interface domains. Studies written in English and published
from January 2010 onward were selected. We explored perspectives of different stakeholder groups, in particular researchers,
research participants, health authorities, and ethics committees. We critically appraised literature included in the systematic review
using the Newcastle-Ottawa scale for cohort and cross-sectional studies, Critical Appraisal Skills Programme for qualitative
studies, Mixed Methods Appraisal Tool for mixed methods studies, and Jadad tool for randomized controlled trials.
Results: A total of 40 studies met our inclusion criteria. Overall, the studies were heterogeneous in the type of study design,
population, intervention, research context, and the tools used. Most of the studies’ populations were research participants (ie,
patients and healthy volunteers). The majority of studies addressed barriers to achieving adequate understanding when using
electronic informed consent. Concerns shared by multiple stakeholder groups were related to the security and legal validity of
an electronic informed consent platform and usability for specific groups of research participants.
Conclusions: Electronic informed consent has the potential to improve the informed consent process in biomedical research
compared to the current paper-based consent. The ethical, legal, regulatory, and user interface perspectives outlined in this review
might serve to enhance the future implementation of electronic informed consent.
Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42020158979;
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=158979
(J Med Internet Res 2020;22(10):e19129) doi: 10.2196/19129
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Introduction
Obtaining informed consent is a fundamental ethical practice
in biomedical research. It is the process of providing meaningful
information to the potential participant in order to enable an
autonomous well-informed decision on whether or not they
wish to participate in the research study [1-3]. Moreover,
informed consent may serve as one of the legal grounds for
processing personal data, as described in articles 6 and 9 of the
General Data Protection Regulation [4]. The primary goal of
informed consent is to truly inform potential research
participants or their representatives about different aspects such
as the study design, study procedures, the risks and benefits,
treatment options, participants’ responsibilities, and the right
to withdraw as well as information regarding data processing
[1,3,4]. Therefore, information must be available in lay
terminology and in a language understandable to the participants
[3]. Long and cumbersome paper-based informed consent
documents are the result of the increasing complexity of clinical
research and the multitude of legal and regulatory requirements
to satisfy informed consent needs [5-7]. Regulatory requirements
refer to those related to the regulatory approval of medicines
[8]. Available evidence has shown that research participants
lack understanding of the key concepts of research studies [7,9].
For this reason, many attempts have been made to improve the
understanding of research participants [10].
Owing to innovations in information technology, different
strategies to consent have been developed, ranging from
involving multimedia to the implementation of quizzes [10].
Research on the use of different multimedia formats to present
information and improve research participants’ understanding
is gaining popularity [10-12]. Recently, the US Food and Drug
Administration (FDA), in collaboration with the Office for
Human Research Protections, issued guidance [13] concerning
electronic informed consent in order to provide a shared and
harmonized approach. Electronic informed consent refers to
electronic systems which may incorporate multimedia in order
to convey information and to obtain informed consent. In this
guidance [13], recommendations are described covering several
aspects related to electronic informed consent such as the
presentation of information, the use of electronic signatures,
identity verification, FDA inspections, and the review process
by ethics committees. The development of an electronic
informed consent platform, enabling participants to give and
manage their electronic informed consent, could offer several
opportunities. First, it could facilitate long-term interaction with
research participants in cases where reconsenting for follow-up
studies is required or for providing research results. Second, it
may truly inform research participants in an interactive, tailored
approach based on the individual’s information needs [14].
Considerable research has been devoted to single aspects
important for electronic informed consent; however, rather less
attention has been paid to integrating information from several
important scientific domains such as ethical, legal, regulatory,
and user interface domains. It is vital to balance the relevant
domains in order to create an electronic informed consent
platform that better informs, empowers, and engages research
participants [15,16]. In the field of research, the ethics
committee plays an important role as it is responsible for
reviewing study protocols to ensure that they meet the ethical,
legal, and regulatory requirements of the country where the
research is being conducted, paying attention to the applicability
of international norms and standards [3]. However, it remains
unclear to what extent ethics committees are familiar with
electronic informed consent and how they will handle electronic
informed consent. Moreover, the involvement of research
participants in the design of an electronic informed consent
platform is of utmost importance as they fulfill a central role in
biomedical research. Personalized human-centered design
enables understanding of the participants’ experiences and
incorporation of their feedback to facilitate a participant-centered
electronic informed consent platform [17].
Despite an increasing number of studies relevant for electronic
informed consent, a comprehensive overview of these studies
across the ethical, legal, regulatory, and user interface domains
is lacking. Hence, the primary outcome of this systematic review
was to provide a descriptive overview of the perspectives of
different stakeholder groups (ie, researchers, research
participants, health authorities, and ethics committee members)
in these different domains with regard to electronic informed
consent in biomedical research. The secondary outcome aimed
to provide recommendations to assist responsible
implementation. Insights of this review may serve as the
foundation to design an electronic informed consent platform,
thereby taking scientific steps forward in view of the
international state-of-the-art.
Methods
This systematic review was reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [18]. The corresponding review protocol
is registered in the International Prospective Register of
Systematic Reviews (PROSPERO CRD42020158979).
Search Strategy
The electronic databases of Web of Science (Core collection),
PubMed, EMBASE, ACM Digital Library, and PsycARTICLES
were searched in order to retrieve potential eligible studies. The
searches for all databases were performed November 14, 2019.
A search string for PubMed was developed and consisted of
Medical Subject Headings terms and free-text words. The search
string was adjusted for use in the other electronic databases. All
search strings were verified by a health sciences librarian. These
search strings consisted of keywords such as electronic
(informed) consent, dynamic (informed) consent, e-consent,
digital (informed) consent, interactive (informed) consent, online
(informed) consent, multimedia, and telemedicine. The search
was restricted to studies published in English after January 1,
2010. This timeframe was justified by the fact that electronic
informed consent in biomedical research gained popularity only
J Med Internet Res 2020 | vol. 22 | iss. 10 | e19129 | p. 2https://www.jmir.org/2020/10/e19129
(page number not for citation purposes)
De Sutter et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
in the last decade and that technology has evolved quite rapidly.
The full search strategy for all databases can be found in
Multimedia Appendix 1.
Study Selection and Criteria
All study types (ie, qualitative, quantitative, and mixed methods)
that discussed the concept of electronic informed consent in
biomedical research covering the ethical, legal, regulatory, and
user interface domains were included. Perspectives of
stakeholders, in particular research participants (ie, patients and
healthy volunteers), researchers, ethics committee members,
and health authorities were considered relevant. We excluded
nonempirical studies and abstracts. All studies retrieved from
the search strategy were imported to EndNote X9 (Clarivate
Analytics) and duplicates were removed. The remaining studies
were uploaded to Rayyan (Qatar Computing Research Institute)
software. Two researchers (EDS and DZ) independently
performed the first screening based on titles and abstracts. In a
second step, studies with full texts available were carefully
reviewed by two researchers (EDS and DZ) and disagreements
were resolved by consensus. When the full texts were not
available, the corresponding authors were contacted. The
reference lists of the included studies were hand searched for
additional studies.
Data Extraction and Analysis
Data extraction was performed independently by two researchers
(EDS and DZ) and was subsequently checked. A dedicated
Excel (Microsoft Inc) data extraction form was used retrieving
the following information for each eligible study: study
identification (first author, title, publication year); study
characteristics (study period, country, design, objective,
scenario); stakeholder group (research participants, researchers,
ethics committee members, health authorities); tool used to
collect information (survey, focus groups, interviews);
intervention (a description of the electronic informed consent
platform); domain being assessed (ethical, legal, regulatory, or
user interface); and ethical, legal, regulatory or user interface
perspectives regarding electronic informed consent
Two researchers (EDS and DZ) carried out data analysis together
using Excel. A combination of deductive and inductive thematic
analysis of the ethical, legal, regulatory, and user interface
perspectives was used, reporting different concepts and the main
findings associated with them. Thematic analysis was conducted
according to the six-phase approach described by Braun and
Clarke [19]. During the first phase, notes were created on the
ethical, legal, regulatory, or user interface perspectives found
in literature. These notes were valuable for the creation of initial
codes in the second step. During the third step, we clustered
these codes to generate broad concepts. Thereafter, the concepts
were thoroughly reviewed and were defined in the fourth and
fifth step. In the sixth and last step of this approach, we provided
a descriptive overview to summarize the concepts found in
literature [19]. Within these concepts, studies reporting similar
findings were grouped together in order to provide a concise
overview of results.
Quality Assessment
Two researchers (EDS and DZ) assessed the quality of all
included studies. Based on the study design, the Critical
Appraisal Skills Programme (CASP) for qualitative studies [20],
Mixed Methods Appraisal Tool (MMAT) for mixed methods
studies [21], and Jadad tool for randomized controlled trials
[22] were used. MMAT and CASP were used to criticize study
aspects such as the aim and the methodology of the study
[20,21]. These aspects were evaluated using a categorical scale
(yes, indeterminate, or no), and thereafter, we converted the
number of positive assessments into percentages. The quality
of randomized controlled trials was assessed by considering the
randomization, blinding, dropouts, and withdrawals.
Randomized controlled trials could receive up to 5 points using
the Jadad tool [22]. The Newcastle-Ottawa scale for cohort
studies and an adapted version of this scale for cross-sectional
studies were applied. Using the Newcastle-Ottawa scale, cohort
and cross-sectional studies were evaluated using the following
quality parameters: selection of study groups, comparability of
study groups, and ascertainment of the outcome. Moreover, this
scale also assessed the statistical test used in cross-sectional
studies. Scores ranged from 0 to 9 for cohort studies and from
0 to 10 for cross-sectional studies [23,24].
Results
Search Results
Our search strategy produced a total of 9984 studies. After the
screening process (Figure 1), 40 studies were included in the
final analysis.
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Figure 1. PRISMA flowchart of the systematic review. eIC: electronic informed consent.
Characteristics of Included Literature
Multimedia Appendix 2 summarizes the main characteristics
for each study. The majority of studies were conducted in the
United States (27 studies), followed by the United Kingdom (3
studies). There was 1 study each in Ireland, Korea, Canada,
Australia, Spain, Germany, and Denmark; 3 studies reported
results from several countries. The designs of the studies
included 10 randomized controlled trials, 10 mixed methods
studies, 10 cross-sectional studies, 9 qualitative studies, and 1
cohort study. Most stakeholder groups involved in the studies
were represented by research participants (26 studies), followed
by researchers (2 studies), and ethics committee members (1
study). In 11 studies, more than 1 of these categories, including
health authorities, were involved. As for the characteristics of
the research participants, 22 studies included different age
categories (range 18-88 years), 3 studies each were conducted
in young and elderly populations, and only 1 study was
conducted in children. No information regarding age was
reported in 5 studies involving research participants. When the
information was provided, we noticed that, in 12 studies, the
majority of research participants had a college degree or more,
in 8 studies the majority of research participants had less than
a college degree, and in 2 studies there was an equal distribution
in education level of the research participants. Meanwhile, in
12 studies there was no information regarding the education
level of the research participants. Studies were conducted in
both female and male populations, except 4 studies that only
included either women or men. The tools used to collect relevant
information varied, based, also, on the study design. Multimedia
Appendix 3 shows an overview of the intervention, scenario,
and tools used.
Quality Assessment
The quality of the included studies varied widely. Among the
randomized controlled trials, only 3 studies [25-27] received a
quality score of 3. Quality scores of 2 and 1 were provided to
1 study [28] and 6 studies [29-34], respectively. The qualitative
studies ranged from satisfying 80% or more of the quality
criteria (6 studies) [35-40] to satisfying 50% to 60% of the
quality criteria (3 studies) [41-43]. Moreover, 3 mixed methods
studies met 80% or more of the quality criteria [16,44,45], 6
studies met from 57% to 71% of the quality criteria [15,46-50],
while 1 met only 43% of the quality criteria [51]. The only
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cohort study had a quality score of 7 [52], while the quality
scores of cross-sectional studies were assessed to be 4 [53-56],
5 [57-61], and 6 [62].
Domain Perspectives
Perspectives of the ethical, legal, regulatory, and user interface
domains were reported using 6 concepts: format, impact on
understanding, acceptability, security and trust, storage, and
content. Due to the cross-disciplinary nature of these
perspectives, they were not reported for each domain
individually as each of these concepts touches on 2 or more
domains.
Format
A range of aspects related to the format were identified in the
literature review. The majority of research participants,
researchers, members of the ethics committee as well as health
authorities believed that the ability to incorporate audio, video,
or graphics in electronic informed consent is a distinct benefit,
especially for vulnerable groups [15,16,28,33,39,43,45,
47-49,57]. Patients who were older adults, for example,
expressed the usefulness of graphics and audio [45]. Research
participants mentioned in a focus group that video and graphics
may be more effective than written text in conveying
information [16]. Moreover, patients involved in a study of
Simon et al [39] indicated that audio narration could be of help
for research participants with poor eyesight or limited literacy.
However, participants argued for caution because background
music and sound effects could be an added distraction [50]. In
contrast, video was considered a multimedia element that might
hold participants’ attention more than a paper-based informed
consent could [33]. Important to consider is the length of the
video, since research participants highlighted that a 5-minute
video was too long [33]. The use of graphics, including icons,
was appreciated by all involved stakeholder groups
[15,16,28,39,43,45,47-49,57]. For instance, the implementation
of a progress bar was advised by researchers to indicate the
different steps of the electronic informed consent form [43]. A
pilot study [48] involving children highlighted the entertainment
of graphics, making the electronic informed consent platform
a pleasure to use. On the contrary, adult patients with fragile X
syndrome, a genetic disorder causing intellectual impairment,
had difficulty understanding aspects of clinical research such
as blinding and randomization explained by several animations
[47].
Furthermore, hyperlinks were identified as an important aspect
of the format by participants and researchers [16,43,56].
Hyperlinks could be used as a video link between researchers
and participants in order to combine an online with a
face-to-face consent process [56]. Moreover, patients engaged
in focus groups elicited hyperlinks as an encouraging way to
seek additional information [16]. Nevertheless, it should be
noted that only 20 out of 491 patients (4.1%) involved in a
randomized controlled trial clicked on 1 or more hyperlinks
[26]. Members of the ethics committee and health authorities
advised avoiding the use of hyperlinks to webpages that may
modify their content [15].
Researchers and ethics committee members as well as research
participants criticized having extensive content during usability
analysis of electronic informed consent platforms [34,54].
Research participants advised using a bullet point format with
access to additional information if desired [28,34,50]. Simple,
concise language should be used to encourage a sufficient level
of understanding [15,28,40,50]. The possibility of marking
information that participants did not understand was considered
useful and was viewed as an opportunity to enhance the
discussion with the research staff [15]. Nonetheless, research
participants and researchers emphasized not losing the personal
connection between researcher and participant [15,50].
Moreover, electronic informed consent offers the possibility to
give information in several languages by using subtitles or
translated text. Although many factors influence participant
recruitment, researchers and research participants believed that
electronic informed consent may facilitate recruitment,
particularly in rare disease research [35]. By translating the
content of electronic informed consent into different languages,
information is available for a large number of individuals
regardless of their geographical setting [35,53].
Little information was provided about the choice of the device
when using an electronic informed consent platform. Two
studies, both of them using touchscreen formats, reported
incorrect end user input [51,53]. Researchers entered incorrect
medical record numbers and patient names containing spelling
errors [53]. A similar case with research participants was
reported; in this particular study [51], several participants
accidentally removed their signature, which contributed to the
majority of errors when using touchscreen devices. Moreover,
research participants who were older adults reported that they
would need training to be able to use a tablet-based consent
process [45].
Impact on Understanding
Electronic informed consent may have an impact on the
understanding of research participants by implementing a quiz,
before signing the consent, to assess the participants’ level of
comprehension [28,35,39,44,55]. However, research participants
argue for caution (to not make it feel like a test) [50]. In addition,
interactive technology and a printed consent form offer the
opportunity to review information giving participants the time
to learn about the research [15,16,37,39,50]. Patients considered
a paper-based form more permanent and suggested
implementing a printout option in the electronic informed
consent technology [39]. In addition, Vanaken et al [15] reported
that some research participants preferred to take a printed
version of the informed consent document home. Hence, the
pressure to give consent immediately was decreased [16]. An
extensive amount of studies investigated barriers related to the
use of electronic informed consent which could prevent research
participants from achieving a reasonable level of understanding
[15,25-28,31-34,39,40,44,45,48,49,52,53,55,60,61]. For the
majority of studies, no barriers were reported
[25-28,31-34,44,48,52]. For example, patients with mental
disorders, of whom the majority had a primary level of
education, were able to make well-informed decisions by using
electronic informed consent [52]. Moreover, patients with
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schizophrenia had better understanding of disclosed information
when using electronic informed consent compared to when
using paper-based informed consent [32]. In a few studies,
barriers impeding adequate comprehension were reported by
research participants, researchers as well as ethics committee
members regarding people with limited computer literacy, visual
or auditory impairment, and regarding the lack of access to
computers or internet [15,39,40,45,53,60,61]. Other reported
barriers to achieving adequate understanding were the attitudes
of research participants looking for additional information after
reading a very concise informed consent and the use of graphics
that may be unclear [47,49,55].
Acceptability
Some researchers had concerns regarding approval of electronic
informed consent as an alternative consent process by ethics
committees [16,61]. In addition, ethics committees themselves
expressed uncertainty about the impact of the audio-visual
aspects on the ethical review process and the review duration
[15,59,61]. The ability to confirm the identity of research
participants consenting remotely may be challenging, especially
for researchers [57]. In general, varying perceptions were
reported regarding the use of electronic signatures. Although
the majority of ethics committee chairpersons enrolled in a study
by Kane et al [59] did not encounter submissions of informed
consent documents containing electronic signatures, a large
number of involved chairs would approve it. However,
researchers and members of ethics committees were unsure
about compliance with local regulations [15,59]. Some
representatives of health authorities supported the use of
electronic signatures while others were concerned about data
privacy [15]. With respect to the research participants, a study
by Haussen et al [60], involving legal authorized representatives
of whom 21 out of 53 representatives (40%) had a low
educational status, stated that for these participants there is an
increased chance of preferring a paper-based informed consent.
Security and Trust
Research participants stressed the importance of trust in the
authenticity of electronic informed consent to share health data
and to agree to take part in the study [36]. This went
hand-in-hand with security of the electronic informed consent
platform, which was a main concern for all stakeholders
[15,34,36,39,40,42,50,61]. A secure platform may enable the
transfer of files, which researchers considered an important
factor in biomedical research [57]. Chhin et al [53] reported
that the electronic informed consent platform that they
developed could only be accessed by using individual user
accounts and passwords. Moreover, researchers mentioned the
need for providing sufficient information on privacy aspects to
potential research participants [43]. According to research
participants, electronic informed consent may enhance trust in
research because of the possibility of returning research
information by using innovative technology [38]. Nevertheless,
Harle et al [26] conducted a randomized controlled trial with
patients receiving standard, interactive-only, or interactive
trust-enhanced electronic informed consent. Trust-enhanced
messages were implemented containing additional information
on data protections, regulations, and training of the research
staff. They indicated there was no effect from the inclusion of
these trust-enhanced messages on data sharing, satisfaction, and
understanding [26].
Storage
According to multiple stakeholders, electronic storage of consent
details constitutes a notable benefit by enabling researchers to
have a trustworthy and traceable overview of the consent status
of participants [15,35]. For example, electronic informed consent
can support online withdrawal, together with documentation of
the reasons for withdrawal [41,46]. Moreover, online storage
improves version control which might reduce the number of
adverse inspection findings by the health authorities.
Nevertheless, health authorities voiced concerns that informed
consent forms may be inaccessible during an inspection [15].
An important feature for researchers and the ethics committee
is to have the ability to control access for specific consent
documents [57]. According to research participants, access to
their own health information is a key benefit of participation
[46]. Research participants requested more transparency
regarding the use of their data [38,58]. They expressed the right
to control the sharing and use of their private health information
[37,42]. Moreover, electronic informed consent enables
researchers to update participants frequently with information
about preliminary results, follow-up studies, and main outcomes
[35]. Nevertheless, the majority of patients with mental
disorders, involved in a study by Sundby et al [62], stated that
they would prefer direct contact with the research staff for
receiving genomic information concerning serious or
life-threatening conditions.
Content
The usefulness of additional content elements such as definitions
was articulated in a focus group involving research participants
who were older adults [45]. Moreover, exposing research
participants to social annotation, such as comments generated
by end users on several aspects of the electronic informed
consent form, was considered important to feel adequately
informed [29]. However, the emotional force communicated in
social annotations has an influence on research participants’
perceptions with regard to information given in electronic
informed consent. Research participants exposed to positive
valence annotations indicated feeling less informed than
participants receiving a combination of positive and negative
valence annotations [30]. Various studies [15,37,58,62] provided
insights into a personalized approach of an electronic informed
consent platform. Research participants stated that they would
like to receive personalized elements and tailored information
such as the display of their name in the electronic informed
consent form or the impact of their contribution on a specific
research question [15,37]. Moreover, Kim et al [58] conducted
a study using an electronic informed consent platform in which
research participants were allowed to modify their preferences
for data sharing. In this study [58], research participants
indicated that a personalized approach could enable participants’
eagerness for data sharing for research purposes. Furthermore,
researchers appreciated the possibility of research participants
indicating what kind of information they would like to obtain
[62].
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Importance of Understanding in Electronic Informed
Consent
The majority of studies paid particular attention to
understanding, considering that it is seen as a crucial point in
enabling participants to give their informed consent. In some
studies [28,33,34,39,44-46,48,55,60,62], the majority of
participants had a high level of education. It should also be
noted that a number of studies [27,29,51] assessing
comprehension did not report the education level of their
participants. Therefore, there might be additional barriers for
less educated participants to achieving an adequate level of
understanding. If research participants are not adequately
informed about a research study, they may be disappointed due
to misconceptions of the benefits. As a result, researchers may
face increased dropout. Moreover, research participants may
distrust ethics committees when they do not put the research
participant at center when reviewing an electronic informed
consent. Literature reported that electronic informed consent
could improve understanding through the opportunity to check
participants’ level of comprehension by using quizzes before
electronically signing the consent form [28,35,39,44,55]. The
implementation of a quiz may prevent research participants
from immediately agreeing to participate in research, not
allowing the content to be reviewed thoroughly. Nevertheless,
meta-analysis of different informed consent interventions
conducted by Nishimura et al [10] showed a significant higher
understanding for paper-based enhanced consent forms including
simplified text and facilitated reading level. A non-significant
increase of understanding was observed for multimedia
interventions. These enhanced consent forms and multimedia
approaches were compared with a control consent process that
consisted of a paper-based informed consent or an already
enhanced informed consent [10]. It would, therefore, seem that
further research is needed to explore the effect on understanding
of an electronic informed consent platform including all of these
aspects, considering the education level, age, health status, and
health literacy of the participant.
Particular Attention to Specific Population Groups
Several studies [15,39,40,45,60,61] included in this review
reported concerns about access to electronic informed consent
for specific population groups. From an ethical point of view,
different population groups need to have the opportunity to be
represented in biomedical research. The possibility for several
population groups to take part in a research study may, first,
broaden their access to treatments, and second, positively impact
the generalizability of research results. Adequate support is
required for participants with, for example, no or limited
computer literacy. Obtaining informed consent in people with
mental disorders remains a challenge that may be overcome
with electronic informed consent. Health authorities believe
that vulnerable populations, which are often underrepresented
in clinical research, might benefit [15]. However, it is important
to highlight that only a limited number of studies
[25,31,32,45,47,48,62] included vulnerable groups who may
have particular requirements. In only 1 pilot study, perceptions
of children regarding the use of graphics were evaluated [48].
Recommendations cannot be inferred from this pilot study
because they require verification in further research. Generally,
electronic informed consent platforms are intended to be used
by multiple dissimilar target groups. The target population varies
in literacy, education, age, health condition, and many other
factors. Therefore, preferences for designing a usable interface
may deviate across the type of end users. Visual factors, such
as the font size or the use of graphics, will differ for research
studies involving older adults, children, or visually impaired
participants.
Personal Connection
Attention needs to be paid to not losing the personal connection
between research participants and research staff. Electronic
informed consent has the opportunity to supplement the existing
paper-based consent process but is not meant to replace it. For
example, research participants may prefer the paper-based
consent document or electronic informed consent facilitated by
a discussion with the research staff to enable an informed
decision. To enhance trust in research or in the authenticity of
an electronic informed consent platform, the personal connection
may play an important role. Moreover, electronic informed
consent has the potential to inform research participants about
early findings, but participants involved in a study by Sundby
et al [62] preferred having direct contact with the research team
if this information was related to life-threatening conditions. In
addition, the online consent form should provide participants
with a link that they can enter to withdraw their consent any
time they desire. Nevertheless, for several types of medication,
it is dangerous to abruptly stop [63]. For this reason, the
interaction between the research participant and the research
team is of utmost importance to prevent withdrawal symptoms
by giving all necessary information. In general, a lack of
face-to-face communication may lead to misunderstanding with
regard to several aspects of a research study.
Guidance Framework
Acceptability of electronic informed consent by the health
authorities was unclear [15,59]. Therefore, analysis of the legal
framework regarding different aspects of electronic informed
consent is required to determine the restrictions in certain
jurisdictions. More research is needed to explore the legal
aspects related to electronic informed consent across several
countries. In addition, uncertainty exists about the review
process of electronic informed consent by ethics committees
[15,59,61]. Due to the lack of experience, it remains unclear
how the evaluation process of ethics committees will be
impacted. It would thus be of interest to investigate which
aspects of the electronic informed consent process ethics
committees would consider for evaluation. General consensus
on the review process of ethics committees is required to
facilitate harmonized review for multicentric studies in which
multiple ethics committees are involved. In addition, researchers
need to receive clarification on which materials they need to
submit to ethics committees. A guidance framework could
reduce the burden of researchers and ethics committees
concerning the preparation and review of electronic informed
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consent and could ensure protection of the rights, safety, and
welfare of human participants.
Privacy by Design
Notable concerns were expressed by several stakeholders
regarding security of electronic informed consent platforms,
and thus data privacy [15,34,36,39,40,42,50,61]. Because
electronic informed consent establishes the opportunity to give
consent remotely, capture of an electronic signature and proof
of identity are challenging. Researchers and ethics committees
raised concerns about low compliance of electronic signature
with local regulations. These concerns may strengthen reluctance
to implement and use electronic informed consent platforms in
biomedical research. In order to secure the platform, potential
security threats need to be identified to counter them in security
software. It is of utmost importance to implement the highest
standards in security and privacy design to prevent fraudulent
use of participants’ health data. Moreover, clarifying the
integrated security and privacy aspects to the research
participants is valuable to reduce these concerns. A breach of
privacy could, for research participants, lead to job loss or
consequences related to their insurance. Moreover, researchers
could be held responsible for misconduct. Ethics committees
and health authorities could also be held responsible, as they
did not look into the security of the electronic informed consent
platform when reviewing or inspecting. In previous years, the
failure to obtain and document the consent of research
participants was part of frequent FDA inspection failures [64].
Owing to online storage, electronic informed consent may
contribute to, for example, better version control and
documentation of the consent process [15,35]. Nevertheless,
controlled access systems need to be implemented to restrict
access for stakeholders for different types of content in order
to respect the privacy of the participants.
Usability
Noteworthy is the discrepancy between quantitative and
qualitative usability testing. Despite the mention of hyperlinks
as an important feature of the user interface in a qualitative
focus group study [16], this feature was barely used in a
randomized controlled trial evaluating different electronic
informed consent platforms [26]. These results suggest using
an iterative design cycle starting with an evaluation of what
participants would consider as useful in the user interface, after
which a usability analysis should be performed. It is crucial to
involve research participants when designing an electronic
informed consent platform to create a user-friendly and
acceptable system. This will support researchers in ensuring an
adequate number of participants in order to detect possible
important clinical findings. Moreover, although research
participants indicated preferring concise information in consent
forms [15,28,40,50], attention needs to be paid to participants
who are not motivated to seek additional information. Specific
measures are needed if input of researchers or research
participants is required when using electronic informed consent
in order to prevent errors. Potential errors are related to devices
used by biomedical research stakeholders and the amount of
manual input required. The use of touchscreen devices might
invoke more inadvertent actions from accidental touches on the
display, compared to those from the use of computers. The
implementation of a quality assurance procedure is highly
recommended in order to avoid incorrect end-user input.
Inclusivity
Language aspects may complicate obtaining informed consent,
and thus recruitment. It requires additional effort to involve
research participants whose primary language is not frequently
used in the informed consent process. To make the informed
consent process more inclusive, subtitles or translated text can
be used in electronic informed consent. Additionally,
intercultural mediation can be considered to reduce the adverse
outcomes of language barriers. An intercultural mediator can
be part of the electronic informed consent process to assist the
linguistic interpretation of information in the electronic informed
consent [65].
Toward Personalized Electronic Informed Consent
An electronic informed consent platform provides an important
means for modifying consent preferences. Electronic informed
consent can be tailored to participants’ needs to address their
preferences. In this way, participants may change different
aspects such as which information they would like to receive,
how they prefer to be contacted, and how often they wish to be
contacted. Research participants indicated that access to their
personal health data is an important motivation to participate
in research studies. By enabling a personalized approach in the
electronic informed consent platform, research participants can
indicate whether they would like to receive this information.
Moreover, electronic informed consent can be personalized for
different kind of diseases. Patient preferences can vary for
disease-specific informed consents. Participants with delicate
health conditions may, for example, require additional
information related to the study and may not be eager to share
their data. Personalization may improve research participants’
engagement and understanding. However, attention needs to be
paid to the review process of such personalized electronic
informed consent in order to avoid a time-consuming process.
Further research that considers several types of end users is
recommended, as electronic informed consent must be tailored
to different population needs. Moreover, electronic informed
consent provides the possibility of updating research participants
with information on an ongoing research study. Nevertheless,
it needs to be investigated how an electronic informed consent
platform can be personalized and how longitudinal interaction
can be assured.
Recommendations
The ethical, legal, regulatory, and user interface perspectives
were converted into recommendations to facilitate
implementation of electronic informed consent in biomedical
research. The recommendations are based upon the 6 concepts
reported in the results and are shown in Table 1.
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Table 1. Recommendations to guide implementation of electronic informed consent in biomedical research.
DescriptionConcept
Format • Implement audio, video, graphics (ie, icons, progress bar) and hyperlinks. Note: do not add audio that may distract
participants, consider the length of the video, create understandable graphics and avoid hyperlinks to webpages with
dynamic content
• Use simple, concise language and implement a bullet point format. Note: provide access to additional information if
desired
• Give the possibility to research participants to highlight information that is difficult to understand in order to facilitate
the discussion with the research staff
• Depending on the research study, make electronic informed consent available in multiple languages by using subtitles
or translated text
• Implement a quality assurance process to check the input of the end user
Impact on understanding • Pay attention to the personal connection between the research participants and the research staff (also refers to secu-
rity and trust)
• Implement quizzes to assess the participants’ level of comprehension. Note: do not let the quizzes feel like an evalu-
ation
• Give the possibility to review information by using interactive technology or the printed electronic informed consent
form
• Guarantee adequate support for people with limited computer literacy, visual/auditory impairment and people who
do not have access to internet or computers
Acceptability • Collaborate with health authorities and ethics committees to create a framework for reviewing and implementing
electronic informed consent
Security and trust • Implement controlled access systems for several stakeholder groups and pay attention to a secured electronic informed
consent platform. Note: provide sufficient information to potential research participants about privacy aspects of the
platform
• Make sure that the secure transfer of files is possible between stakeholder groups
Storage • Provide online storage of the informed consent
• Support online withdrawal with documentation of the reasons for withdrawal
• Pay attention to transparency regarding the use of participants’health information and their right to control the sharing
and use of this information
• Implement the possibility to update research participants frequently with information about preliminary results, follow-
up studies and main outcomes
Content • Implement definitions
• Implement social annotations but mind the emotional force
• Implement a personalized approach (eg, by letting the participants indicate what kind of information they would like
to receive)
Limitations
Our systematic review only included literature published in
English. As a consequence, selection bias could have been
introduced because it is possible that information specific to
the ethical, legal, regulatory, or user interface domain of
electronic informed consent in languages other than English
was not identified. Another limitation was that the
methodological quality of the included studies was rated overall
as moderate which needs to be considered when interpreting
the reported findings. Most of the studies had small sample
sizes, which could be an issue for the generalizability of results.
The studies included in the review had a high level of
heterogeneity among them, which is the reason why a
descriptive analysis was conducted. The differences in study
designs, research fields and contexts, populations, and tools
used to assess the results may have impacted the findings
reported by each study.
Conclusions
This systematic review highlights different opportunities and
challenges for responsible implementation of electronic
informed consent in biomedical research. Electronic informed
consent provides the possibility of enforcing a personalized
approach and supporting a longitudinal interaction with research
participants. Findings suggest that electronic informed consent
may have a beneficial impact on the consent process as long as
some requirements are fulfilled. Special attention needs to be
paid to specific population groups and to personal interaction
with research staff. Future high-quality research, especially
using randomized controlled trials, is required to provide
information that may encourage the use of electronic informed
consent for vulnerable groups.
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